On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar

With Gilead Sciences on the verge of an FDA decision for its liver disease drug seladelpar, the company has paid Johnson & Johnson $320 million to exit an 18-year-old licensing agreement on the compound.